Novo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD

High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally Combined in-licensing and financing for a novel long-acting clinical stage monoclonal antibody targeting TSLP ligand as well as building a discovery pipeline of…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.